Literature DB >> 23268705

Neurochemical profile of dementia pugilistica.

Tyler A Kokjohn1, Chera L Maarouf, Ian D Daugs, Jesse M Hunter, Charisse M Whiteside, Michael Malek-Ahmadi, Emma Rodriguez, Walter Kalback, Sandra A Jacobson, Marwan N Sabbagh, Thomas G Beach, Alex E Roher.   

Abstract

Dementia pugilistica (DP), a suite of neuropathological and cognitive function declines after chronic traumatic brain injury (TBI), is present in approximately 20% of retired boxers. Epidemiological studies indicate TBI is a risk factor for neurodegenerative disorders including Alzheimer disease (AD) and Parkinson disease (PD). Some biochemical alterations observed in AD and PD may be recapitulated in DP and other TBI persons. In this report, we investigate long-term biochemical changes in the brains of former boxers with neuropathologically confirmed DP. Our experiments revealed biochemical and cellular alterations in DP that are complementary to and extend information already provided by histological methods. ELISA and one-dimensional and two dimensional Western blot techniques revealed differential expression of select molecules between three patients with DP and three age-matched non-demented control (NDC) persons without a history of TBI. Structural changes such as disturbances in the expression and processing of glial fibrillary acidic protein, tau, and α-synuclein were evident. The levels of the Aβ-degrading enzyme neprilysin were reduced in the patients with DP. Amyloid-β levels were elevated in the DP participant with the concomitant diagnosis of AD. In addition, the levels of brain-derived neurotrophic factor and the axonal transport proteins kinesin and dynein were substantially decreased in DP relative to NDC participants. Traumatic brain injury is a risk factor for dementia development, and our findings are consistent with permanent structural and functional damage in the cerebral cortex and white matter of boxers. Understanding the precise threshold of damage needed for the induction of pathology in DP and TBI is vital.

Entities:  

Mesh:

Year:  2013        PMID: 23268705      PMCID: PMC3684215          DOI: 10.1089/neu.2012.2699

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  125 in total

1.  TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Brandon E Gavett; Robert A Stern; Christopher J Nowinski; Robert C Cantu; Neil W Kowall; Daniel P Perl; E Tessa Hedley-Whyte; Bruce Price; Chris Sullivan; Peter Morin; Hyo-Soon Lee; Caroline A Kubilus; Daniel H Daneshvar; Megan Wulff; Andrew E Budson
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

2.  Unmyelinated axons show selective rostrocaudal pathology in the corpus callosum after traumatic brain injury.

Authors:  Thomas M Reeves; Terry L Smith; Judy C Williamson; Linda L Phillips
Journal:  J Neuropathol Exp Neurol       Date:  2012-03       Impact factor: 3.685

3.  Alzheimer disease paired helical filament core structures contain glycolipid.

Authors:  D R Sparkman; W J Goux; C M Jones; C L White; S J Hill
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

4.  Frontal cortex neuropathology in dementia pugilistica.

Authors:  Tommy Saing; Malcolm Dick; Peter T Nelson; Ronald C Kim; David H Cribbs; Elizabeth Head
Journal:  J Neurotrauma       Date:  2012-04-10       Impact factor: 5.269

Review 5.  Traumatic brain injury: can the consequences be stopped?

Authors:  Eugene Park; Joshua D Bell; Andrew J Baker
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

Review 6.  Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment.

Authors:  Gary B Kaplan; Jennifer J Vasterling; Priyanka C Vedak
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

7.  Traumatic axolemmal and cytoskeletal derangement in myelinated axons of human oedematous cerebral cortex and loss of consciousness. An electron microscopic study using cortical biopsies.

Authors:  O J Castejón; G Acurero
Journal:  J Submicrosc Cytol Pathol       Date:  2004 Jul-Oct

8.  Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation.

Authors:  Daniel Paris; James Humphrey; Amita Quadros; Nikunj Patel; Robert Crescentini; Fiona Crawford; Michael Mullan
Journal:  Neurol Res       Date:  2003-09       Impact factor: 2.448

Review 9.  Neprilysin and amyloid beta peptide degradation.

Authors:  Louis B Hersh; David W Rodgers
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

Review 10.  Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation.

Authors:  M Inagaki; Y Nakamura; M Takeda; T Nishimura; N Inagaki
Journal:  Brain Pathol       Date:  1994-07       Impact factor: 6.508

View more
  11 in total

Review 1.  A Review of the Effectiveness of Neuroimaging Modalities for the Detection of Traumatic Brain Injury.

Authors:  Franck Amyot; David B Arciniegas; Michael P Brazaitis; Kenneth C Curley; Ramon Diaz-Arrastia; Amir Gandjbakhche; Peter Herscovitch; Sidney R Hinds; Geoffrey T Manley; Anthony Pacifico; Alexander Razumovsky; Jason Riley; Wanda Salzer; Robert Shih; James G Smirniotopoulos; Derek Stocker
Journal:  J Neurotrauma       Date:  2015-09-30       Impact factor: 5.269

2.  Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank.

Authors:  Kevin F Bieniek; Owen A Ross; Kerry A Cormier; Ronald L Walton; Alexandra Soto-Ortolaza; Amelia E Johnston; Pamela DeSaro; Kevin B Boylan; Neill R Graff-Radford; Zbigniew K Wszolek; Rosa Rademakers; Bradley F Boeve; Ann C McKee; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-10-30       Impact factor: 17.088

3.  Frontal Traumatic Brain Injury Increases Impulsive Decision Making in Rats: A Potential Role for the Inflammatory Cytokine Interleukin-12.

Authors:  Cole Vonder Haar; Kris M Martens; Lara-Kirstie Riparip; Susanna Rosi; Cheryl L Wellington; Catharine A Winstanley
Journal:  J Neurotrauma       Date:  2017-05-24       Impact factor: 5.269

Review 4.  Polypathology and dementia after brain trauma: Does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy?

Authors:  Patricia M Washington; Sonia Villapol; Mark P Burns
Journal:  Exp Neurol       Date:  2015-06-16       Impact factor: 5.330

Review 5.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

Review 6.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

7.  Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.

Authors:  Nicholas M Kanaan; Kristine Cox; Victor E Alvarez; Thor D Stein; Sharra Poncil; Ann C McKee
Journal:  J Neuropathol Exp Neurol       Date:  2016-01       Impact factor: 3.685

8.  Differential Regional Responses in Soluble Monomeric Alpha Synuclein Abundance Following Traumatic Brain Injury.

Authors:  S W Carlson; H Q Yan; Y Li; J Henchir; X Ma; M S Young; M D Ikonomovic; C E Dixon
Journal:  Mol Neurobiol       Date:  2020-09-19       Impact factor: 5.590

9.  Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease.

Authors:  Sandra A Acosta; Naoki Tajiri; Ike de la Pena; Marina Bastawrous; Paul R Sanberg; Yuji Kaneko; Cesar V Borlongan
Journal:  J Cell Physiol       Date:  2015-05       Impact factor: 6.384

10.  Traumatic brain injury, neuroimaging, and neurodegeneration.

Authors:  Erin D Bigler
Journal:  Front Hum Neurosci       Date:  2013-08-06       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.